Valuation : Indivior Pharmaceuticals, Inc.

Market Cap 4.12B 3.55B 3.32B 3.03B 5.72B 393B 5.74B 39.45B 15.39B 199B 15.45B 15.11B 658B P/E 2026 *
9.37x
P/E 2027 * 8.49x
Enterprise Value 4.1B 3.54B 3.31B 3.03B 5.7B 392B 5.72B 39.33B 15.34B 198B 15.4B 15.07B 656B EV / Sales 2026 *
3.08x
EV / Sales 2027 * 2.53x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
1 week-6.79%
1 month-15.17%
1 week 30.2
Extreme 30.2
31.6
1 month 30.2
Extreme 30.2
36
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%-6.79% - - 4.12B
-1.75%-7.94%+56.14%+107.14% 1,047B
-0.26%-2.46%+49.57%+64.72% 646B
+0.02%-4.02%+19.80%+72.75% 451B
-1.55%-4.64%+35.74%+35.69% 355B
-0.48%-3.08%+21.00%+37.57% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.21%-3.38%+49.46%+67.29% 234B
-1.21%-2.79%-20.32%-54.33% 203B
-1.17%-2.09%+27.47%+87.86% 181B
Average -0.83%-2.68%+26.71%+47.80% 406.59B
Weighted average by Cap. -0.90%-3.46%+35.89%+63.92%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.08B 982M 1.85B 127B 1.86B 12.77B 4.98B 64.26B 5B 4.89B 213B 1.4B 1.21B 1.13B 1.03B 1.94B 134B 1.95B 13.42B 5.23B 67.52B 5.25B 5.14B 224B
Net income 474M 409M 383M 350M 659M 45.33B 661M 4.55B 1.77B 22.88B 1.78B 1.74B 75.87B 530M 457M 428M 391M 736M 50.65B 739M 5.08B 1.98B 25.57B 1.99B 1.95B 84.78B
Net Debt -12.5M -10.77M -10.1M -9.22M -17.37M -1.19B -17.42M -120M -46.75M -603M -46.93M -45.91M -2B -570M -491M -461M -420M -792M -54.48B -794M -5.46B -2.13B -27.5B -2.14B -2.09B -91.18B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Date Price Change
28/08/26 30.20 -1.31%
27/08/26 €30.60 -1.29%
26/08/26 €31.00 0.00%
25/08/26 €31.00 -1.90%
24/08/26 €31.60 -2.47%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.87USD
Average target price
49.00USD
Spread / Average Target
+40.52%

Quarterly revenue - Rate of surprise